J. Goldman & CO LP Tcr2 Therapeutics Inc. Transaction History

J. Goldman & CO LP

  • $3.21 Billion
  • Q3 2024

A detailed history of J. Goldman & CO LP transactions in Tcr2 Therapeutics Inc. stock. As of the latest transaction made, J. Goldman & CO LP holds 40,800 shares of TCRR stock, worth $0. This represents 0.04% of its overall portfolio holdings.

Number of Shares
40,800
Holding current value
$0
% of portfolio
0.04%

Shares

0 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
No transaction found.

About TCR2 THERAPEUTICS INC.

TCRR Quotes by TradingView
  • Ticker TCRR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,606,400
  • Description
  • TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...
More about TCRR
Track This Portfolio

Track J. Goldman & CO LP Portfolio

Follow J. Goldman & CO LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

News

Stay updated on J. Goldman & CO LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email